Drugs

, Volume 74, Issue 9, pp 951–961

Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals

Current Opinion

Abstract

Approximately 30 % of HIV-infected patients are co-infected with hepatitis C virus (HCV). After the release of highly active antiretroviral therapy, liver disease has become the leading cause of morbidity and mortality in HIV patients. Prior to 2011, HCV treatment with pegylated-interferon and ribavirin in HCV/HIV co-infected patients only allowed 14–38 % of patients with HCV genotype 1 to achieve a sustained virologic response (SVR). Additionally, treatment was commonly discontinued as a result of adverse events. Recently, simeprevir and sofosbuvir have been approved by the US Food and Drug Administration (FDA) for HCV mono-infection. Sofosbuvir has been given FDA approval in co-infected patients offering unprecedented SVR rates and the potential for interferon-free therapy. HCV therapies that are in the pipeline offer improved treatment times, safety profiles, and rates of SVR. Despite these improvements, several new issues including adherence, drug–drug interactions with antiretroviral therapies, adverse events, resistance, and patient selection may complicate therapy. This article reviews the current status of direct-acting antivirals (DAA)-containing regimens for HIV/HCV co-infected patients in the USA. New results investigating telaprevir and boceprevir are also discussed as they are relevant for locations where new DAAs are not available. The impact future interferon-free therapies may have on co-infected patients is also discussed.

References

  1. 1.
    Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14(4):195–207.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (London, England). 2010;24(10):1537–48.Google Scholar
  3. 3.
    Staples CT, Jr., Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29(1):150–4.Google Scholar
  4. 4.
    Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192(6):992–1002.PubMedCrossRefGoogle Scholar
  5. 5.
    Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198(9):1337–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group. Hepatology. 1999;30(4):1054–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Dieterich DT, Rodriguez-Torres M, Sulkowski MS, Torriani F, Wat C, Patel KM, et al. In APRICOT and PARADIGM 99% of HIV-HCV co-infected patients with an SVR12 achieved an SVR24 validating SVR12 as an endpoint for trials in this population. Hepatology. 2012;56:587A–8A.Google Scholar
  8. 8.
    Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013;58(6):1104–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;55(5):728–36.PubMedCrossRefGoogle Scholar
  11. 11.
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012;56(2):320–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol. 2012;27(7):1233–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839–48.PubMedCrossRefGoogle Scholar
  15. 15.
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18(13):F27–36.Google Scholar
  18. 18.
    Ioannou G, Scott J, Yang Y, Green P, Beste L. Antiviral treatment for hepatitis C virus in HIV/HCV co-infected patients. 64th Annual Meeting of the American Association of the Study of Liver Diseases, Washington, DC; 2013.Google Scholar
  19. 19.
    American Association for the Study of Liver Diseases and the Infectious Diseases Society of America: recommendations for testing, managing, and treating hepatitis C2014. http://www.hcvguidelines.org/full-report-view.
  20. 20.
    Galan RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. JMCP. 2013;19(6):448–53.PubMedGoogle Scholar
  21. 21.
    Jacobson IM, Ghalib RH, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology. 2013;58(6):1379A–80A.Google Scholar
  22. 22.
    Zeuzem S, Dusheiko G, Salupere R, Mangi A, Flisiak R, Hyland R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. 64rd Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC; 2013.Google Scholar
  23. 23.
    Hulskotte EGJ, Feng HP, Xuan FJ, van Zutven M, Treitel MA, Hughes EA, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56(5):718–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Dieterich DT, Tural C, Nelson M, Arasteh K, Soriano V, Guardiola JM, et al. Faldaprevir plus pegylated interferon alfa-2a/ribavirin in HIV/HCV coinfection: STARTVerso4. 21st Conference on Retroviruses and Opportunistic Infections, Boston (MA); 2014.Google Scholar
  25. 25.
    Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug–drug interactions. CROI, Boston (MA); 2011.Google Scholar
  26. 26.
    Simeprevir package insert. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed 30 Dec 2014.
  27. 27.
    Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011;141(3):881–9 e1.Google Scholar
  28. 28.
    Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 2014;146:744–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.PubMedCrossRefGoogle Scholar
  30. 30.
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.PubMedCrossRefGoogle Scholar
  31. 31.
    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86–96.PubMedGoogle Scholar
  33. 33.
    Montes M, Nelson M, Girard P, Sasadeusz J, Horban A, Grinsztejn B, et al. Telaprevir combination therapy in treatment-naive and -experienced patients co-infected with hepatitis C virus and HIV: week 12 analysis of INSIGHT. 64th Annual Meeting of the American Association of the Study of Liver Diseases, Washington, DC; 2013.Google Scholar
  34. 34.
    van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antiviral Ther. 2013;18(4):553–60.CrossRefGoogle Scholar
  35. 35.
    Kakuda T, Leopold L, Nijs S. Pharmacokinetic interaction between etravirin or rilpivirine and telaprevin in health volunteers: a randomised, two-way crossover trial. 13th PK Workshop, Barcelona; 2012.Google Scholar
  36. 36.
    Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):431–9.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–17.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597–605.PubMedCrossRefGoogle Scholar
  40. 40.
    Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol. 2011;54(6):1114–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Sulkowski MS, Bourliere M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology. 2013;57(6):2155–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology. 2013;57(6):2143–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Dieterich DT, Rockstroh JK, Orkin C, Gutierrez F, Klein M, Reynes J, et al. Simeprevir plus pegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212). 21st Conference on Retroviruses and Opportunistic Infections, Boston (MA); 2014.Google Scholar
  44. 44.
    Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014.Google Scholar
  45. 45.
    Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without pegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2013.Google Scholar
  46. 46.
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol. 1996;91(12):2563–8.PubMedGoogle Scholar
  48. 48.
    Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008;47(1):36–49.PubMedCrossRefGoogle Scholar
  49. 49.
    Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC): NCT01514890. J Hepatol. 2013;59(3):434–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, et al. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther. 2014;39(2):209–16.PubMedCrossRefGoogle Scholar
  51. 51.
    Roux P, Lions C, Cohen J, Winnock M, Salmon-Ceron D, Bani-Sadr F, et al. Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort. Antiviral Ther. 2013.Google Scholar
  52. 52.
    Pizzirusso M, Lin J, Head C, Marcus SM, Ahmed S, Brau N, et al. Impact of hepatitis C treatment initiation on adherence to concomitant medications. J Assoc Nurses AIDS Care. 2014;25(1):23–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Icahn School of Medicine at the Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations